首页> 外文期刊>Medicina Fluminensis >Treatment of ocular surface squamous neoplasia: Case reportof ocular surface squamous neoplasia: Case report
【24h】

Treatment of ocular surface squamous neoplasia: Case reportof ocular surface squamous neoplasia: Case report

机译:眼表鳞状鳞癌的治疗:病例报告

获取原文
           

摘要

Saxc5xbeetakAim: Ocular surface squamous neoplasia (OSSN) is a term that encompasses a wide and varied spectrum of very rare dysplastic disease of cornea and conjunctiva, ranging from conjunctival intraepithelial neoplasia (CIN), carcinoma in situ (CIS) to invasive squamous cell carcinoma (SCC) of conjunctiva and/or cornea. Case report: In our case report, we present squamous cell carcinoma of the conjunctiva and cornea in a 78-year old man. Our diagnostic algorithm included: slit lamp and fundus examination, gonioscopy, impression cytology (IC) andmagnetic resonance imaging (MRI). The patient underwentsurgical excisional biopsy of the lesion and intraoperativecryotherapy of the cut conjunctival edges and sclera-conjuctiva base region. Following surgical therapy, we started topical 0.02 % (0.2 mg/ml) Mitomycin C (MMC) application daily for 14 days. Control excisional biopsy of conjunctival edge and abrasion of involved cornea were performed following the last day of topical chemotherapy. Our controlexcisional biopsyrevealed tumor positive corneal tissue and the second cycle of topical 0.04 % (0.4 mg/ml) MMCchemotherapy wasstarted for next 3 weeks. The patient has been followed-up for 20 months through monthlyxc3xa2xe2x82xacxe2x80x9cbased visits, with no recurrence of the disease. Conclusions: OSSN is a surgical challenge requiring a specialized xc3xa2xe2x82xacxc2x98no-touchxc3xa2xe2x82xacxe2x84xa2 (NT) technique. In our case, the combination of surgical excision with intraoperative cryotherapy and topical chemotherapy with 0.02 % MMC application for 14 days, completed with second cycle of topical 0.04 % MMC drops for the next 21 days given the positive control biopsy, proved to be a good choice for eradication of OSSN with accurate further monitoring of the patient.
机译:Sa xc5 xbeetak目的:眼表鳞状上皮增生(OSSN)这个术语涵盖了非常广泛的,非常罕见的角膜和结膜增生异常疾病,从结膜上皮内瘤变(CIN),原位癌(CIS)到浸润性结膜和/或角膜鳞状细胞癌(SCC)。病例报告:在我们的病例报告中,我们呈现了一名78岁男性的结膜和角膜鳞状细胞癌。我们的诊断算法包括:裂隙灯和眼底检查,角膜镜检查,印象细胞学(IC)和磁共振成像(MRI)。患者对病灶进行了手术切除活检,并对结膜边缘和巩膜结膜基部区域进行了术中冷冻治疗。手术治疗后,我们开始每天局部应用0.02%(0.2 mg / ml)丝裂霉素C(MMC)施用14天。局部化疗的最后一天后,进行结膜边缘对照切除活检和累及角膜擦伤。在接下来的3周内,我们开始进行对照切除的活检透液的肿瘤阳性角膜组织和局部0.04%(0.4 mg / ml)MMC化疗的第二个周期。该患者已通过基于每月 xc3 xa2 xe2 x82 xac xe2 x80 x9c的随访进行了20个月的随访,该病没有复发。结论:OSSN是一项外科手术挑战,需要专门的 xc3 xa2 xe2 x82 xac xc2 x98no-touch xc3 xa2 xe2 x82 xac xe2 x84 xa2(NT)技术。在我们的案例中,结合手术切除术,术中冷冻疗法和局部化疗联合0.02%MMC施用14天,并在给予阳性对照活检的情况下在接下来的21天第二轮局部使用0.04%MMC滴剂完成,这被证明是一个很好的方法准确地进一步监测患者以消除OSSN的最佳选择。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号